Recruitment update of AHEAD

Area of Science:

• Hematology
• Clinical Trials
• Pharmacoeconomics

Background:

• Hemophilia A requires long-term management strategies.
• Assessing real-world effectiveness and safety of treatments is crucial.
• Long-term outcome data for recombinant factor VIII products are valuable.

Purpose of the Study:

• To gather long-term data on joint health in hemophilia patients.
• To evaluate health-related quality of life (HR-QoL) and comorbidities.
• To assess the effectiveness and safety of ADVATE (octocog alfa) in routine clinical practice.

Main Methods:

• Multicenter, prospective, non-interventional study design.
• Enrollment of up to 500 patients in Germany and 350 in other European countries.
• Four-year follow-up period for each enrolled patient.

Main Results:

• Recruitment ongoing through end of 2015.
• Data collection focuses on joint health, HR-QoL, and comorbidities.
• Safety and effectiveness of ADVATE (octocog alfa) are primary endpoints.

Conclusions:

• The AHEAD study will provide valuable long-term data on hemophilia management.
• Findings will inform clinical practice regarding ADVATE (octocog alfa) use.
• The study contributes to understanding long-term outcomes in hemophilia care.